NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.
NextPoint Therapeutics has raised $42.5M in total funding. The most recent round was Series B. The last funding was announced in February 2024.
NextPoint Therapeutics's investors include Catalio Capital Management, Sanofi Ventures, Invus, MPM Capital, Sixty Degree Capital.
NextPoint Therapeutics is headquartered in Cambridge, United States.
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.
NextPoint Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NextPoint Therapeutics — Funding & Investors." VCBacked, February 14, 2024, https://www.vcbacked.co/company/nextpoint-therapeutics. Accessed September 29, 2026.
VCBacked. (2024). NextPoint Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/nextpoint-therapeutics
{{cite web |title=NextPoint Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nextpoint-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated